<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04152265</url>
  </required_header>
  <id_info>
    <org_study_id>6/2019</org_study_id>
    <nct_id>NCT04152265</nct_id>
  </id_info>
  <brief_title>Mycotoxin Exposure and Dietary Habits in Colorectal Cancer Prevention and Development Among Polish Population</brief_title>
  <official_title>Mycotoxin Exposure and Dietary Habits in Colorectal Cancer Prevention and Development Among Polish Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Warmia and Mazury in Olsztyn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Provincial Specialist Hospital in Olsztyn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health Republic of Poland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Warmia and Mazury in Olsztyn</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is the determination of the zearalenone and its metabolites (α and β)
      level in the blood plasma and faeces of patients at increased risk of cancer, in relation to
      the nutrition data (FFQ) and information on the quality of life dependent on health
      (WHOQOL-BREF).

      The study is performer within the framework of the Polish Colonoscopy Screening Program.
      Within the study 100 volunteers between 50 and 65 years of age. while, the colonoscopies will
      be performed in Provincial Specialist Hospital in Olsztyn. Patients with positive test
      result, who have been diagnosed with polyps or cancer, will be assigned to risk group. The
      study has been approved by a local bioethics committee.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Completion of the assigned screening strategy</measure>
    <time_frame>Within 8 weeks of enrollment</time_frame>
    <description>Completion of the assigned screening strategy within 8 weeks of enrollment defined as:
* current screening strategy: documented screening colonoscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analysis of the concentration of the mycotoxin</measure>
    <time_frame>5 month</time_frame>
    <description>Determination of the concentration and a profile of the mycotoxin using the high-performance liquid chromatography coupled with the mass spectrometry (HPLC-MS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characteristics of gut bacterial</measure>
    <time_frame>6 month</time_frame>
    <description>The presence of bacterial DNA in the samples will be confirmed using real-time polymerase chain reaction (RT-PCR). Microbial diversity will be study by sequencing the amplified V3-V4 region of the 16S rRNA gene by using primers 16S. Next, the amplicon pools will be prepared for sequencing and the size and quantity of the amplicon library will be assessed on NGS MiSeq.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of anthropometric data</measure>
    <time_frame>4 weeks</time_frame>
    <description>The anthropometric data will be determined using the professional body mass composition analyser. Based on the obtained data will be calculated Body Mass Index (BMI), which will be expressed in kg/m^2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Colorectal Cancer, Somatic (Diagnosis)</condition>
  <arm_group>
    <arm_group_label>No Intervention: Current screening practice.</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patients will be asked to complete the Food Frequency Questionnaire (FFQ) and the questionnaire about The World Health Organization Quality Of Life (WHOQOL-BREF), also and will be collected the demographic and anthropometric data</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental: Sequential screening strategy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>People aged between 50-65, will take part in the study. Patients, which will take in a screening colonoscopy, will be divided into two groups according to the result obtained. The first group, will be constitute the patients with a positive test result, while the second group (control) will be constitute the patients with the negative test result. In addition, from the Subjects the samples of blood and faeces will be collected.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>colonoscopy</intervention_name>
    <description>colonoscopy</description>
    <arm_group_label>Experimental: Sequential screening strategy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>questionnaires</intervention_name>
    <description>complete the two questionnaires (Food Frequency Questionnaire (FFQ) and the questionnaire of The World Health Organization Quality of Life (WHOQOL-BREF)</description>
    <arm_group_label>No Intervention: Current screening practice.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>demographic data collections</intervention_name>
    <description>completing the demographic questionnaire</description>
    <arm_group_label>No Intervention: Current screening practice.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>anthropometric data collections</intervention_name>
    <description>For the determination of anthropometric data will be used a professional body mass composition analyser (Seca,Hamburg, Germany)</description>
    <arm_group_label>No Intervention: Current screening practice.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Collecte the biological samples</intervention_name>
    <description>blood and faeces collections</description>
    <arm_group_label>Experimental: Sequential screening strategy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women aged from 50 to 65 years residing in Poland.

        Exclusion Criteria:

          -  subjects requiring long-term care due to somatic, mental retardation or other mental
             illness.

          -  history of colorectal resection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tomasz Sawicki, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Human Nutrition, Faculty of Food Science, University of Warmia and Mazury</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tomasz Sawicki, PhD</last_name>
    <phone>+48 89 524 55 19</phone>
    <email>tomasz.sawicki@uwm.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katarzyna Przybyłowicz, Prof</last_name>
    <phone>+48 89 524 55 21</phone>
    <email>katarzyna.przybylowicz@uwm.edu.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Provincial Specialist Hospital in Olsztyn</name>
      <address>
        <city>Olsztyn</city>
        <zip>10-561</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tomasz Arłukowicz, MD, PhD</last_name>
      <phone>+48 89 53 86 557</phone>
      <email>tarlukowicz@wss.olsztyn.pl</email>
    </contact>
    <investigator>
      <last_name>Katarzyna Przybyłowicz, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Łukasz Zielonka, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Magdalena Gajęcka, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomasz Arłukowicz, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tomasz Sawicki, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>November 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2019</study_first_posted>
  <last_update_submitted>November 2, 2019</last_update_submitted>
  <last_update_submitted_qc>November 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Warmia and Mazury in Olsztyn</investigator_affiliation>
    <investigator_full_name>Tomasz Sawicki</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>colorectal cancer</keyword>
  <keyword>zearalenone</keyword>
  <keyword>mycotoxin</keyword>
  <keyword>gastrointestinal bacterial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

